Key result
Specific genetic and epigenetic markers are linked to CVD progression following preeclampsia.
Why the study?
Women with prior preeclampsia have up to five times the risk of later-life cardiovascular disease, but studies investigating their shared genomic variation over time are limited.
Are specific genomic variations associated with the progression to cardiovascular disease in women with a history of preeclampsia?
Systematic Review
Are specific genomic variations associated with the progression to cardiovascular disease in women with a history of preeclampsia?
This systematic review highlights specific genomic variations, including genes, microRNAs, and methylated regions, that may underlie the progression from preeclampsia to later-life cardiovascular disease, while emphasizing the need for longitudinal studies.
Answers are grounded in this paper and cite their sources.
Should not yet guide post-preeclampsia risk stratification; leaves open validation of identified markers in prospective cohorts.
Background Women with a history of preeclampsia (PE) have been shown to have up to five times the risk of developing later-life cardiovascular disease (CVD). While PE and CVD are known to share clinical and molecular characteristics, there are limited studies investigating their shared genomics (genetics, epigenetics or transcriptomics) variation over time. Therefore, we sought to systematically review the literature to identify longitudinal studies focused on the genomic progression to CVD following PE. Methods A literature search of primary sources through PubMed, Scopus, Web of Science and Embase via OVID was performed. Studies published from January 1, 1980, to July 28, 2023, that investigated genomics in PE and CVD were eligible for inclusion. Included studies were screened based on Cochrane systematic review guidelines in conjunction with the PRISMA 2020 checklist. Eligible articles were further assessed for quality using the Newcastle-Ottawa scale. Results A total of 9,231 articles were screened, with 14 studies subjected to quality assessment. Following further evaluation, six studies were included for the final review. All six of these studies were heterogeneous in regard to CVD/risk factor as outcome, gene mapping approach, and in different targeted genes. The associated genes were RGS2 , LPA , and AQP3 , alongside microRNAs miR-122-5p, miR-126-3p, miR-146a-5p, and miR-206. Additionally, 12 differentially methylated regions potentially linked to later-life CVD following PE were identified. The only common variable across all six studies was the use of a case-control study design. Conclusions Our results provide critical insight into the heterogeneous nature of genomic studies investigating CVD following PE and highlight the urgent need for longitudinal studies to further investigate the genetic variation underlying the progression to CVD following PE.
No takes yet. Share an insight, caveat, or question.
Krishnamurthy et al. (2023) conducted a systematic review in Cardiovascular disease following preeclampsia. Genomic variation (genetic, epigenetic, transcriptomic) vs. Absence of genomic variation or normotensive pregnancy history was evaluated on Progression to cardiovascular disease endpoints or CVD risk factors. A systematic review of six heterogeneous case-control studies identified specific genes (RGS2, LPA, AQP3), microRNAs, and differentially methylated regions associated with the progression to cardiovascular disease following preeclampsia.
Synapse has enriched 10 related papers. Consider them for comparative context: